 |
 |
 |
 |
|
|
|
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Your Online Resource for Diabetes Treatment
Home > Search >  |
|
 |
Articles |
 |
Events |
 |
Slides |
 |
Misc. Content |
| Site Match | 768 Records found: [< 1 2 3 4 5 6 > of 31 Pages] |
 |
1. T418-09 CME CE Event Registration: Incretin-Based Therapies: New Options for Glycemic Control in Type 2 Diabetes William C. Gong, PharmD Arlington, Texas This unique forum will take place on: DATE: Thursday, May 1, 2008 TIME: 6:30PM-9:00PM >... ... |
|
2. Mary's Test This is a test. ... |
 |
3. Treating Type 2 Diabetes General Principles Treating Type 2 Diabetes: General Principles Treatment of diabetes involves re-establishing a normal balance between insulin sensitivity and insulin levels (getting back on the curve). Traditional pharmacotherapy has focused on increasing insulin levels with sulfonylurea agents or exogenous insulin (vertical arrow) to re-establish euglycemia with hyperinsulinemia. More recently, drugs such as pioglitazone, ... ... |
|
4. ABCD Trial Comparison of Nisoldipine and Enalapril Effects on MI in Patients With Type 2 Diabetes and Hypertension Type 2 Diabetes and Hypertension The ABCD Trial was designed to evaluate effects of moderate and intensive BP control on changes in the creatinine clearance rate among both normotensive and hypertensive patients with type 2 diabetes. Patients were treated with either a calcium-channel blocker or an ACE inhibitor. It was noted that the rate of MI among patients who received nisoldipine did ... ... |
|
5. Sulfonylureas MOA ... |
|
6. Prevalence of Retinopathy by Duration of Type 2 Diabetes Prevalence of Retinopathy by Duration of Type 2 Diabetes Diabetic retinopathy is the major antecedent of blindness in patients with diabetes. In a representative sample of people in whom diabetes (predominantly type 2 disease) developed after age 30 in Wisconsin in the 1980s, rates of any and proliferative retinopathy increased with the duration of known diabetes. In the same cross-sectional study, retinopathy rates after 15 to ... ... |
|
7. Type 2 Diabetes Prevention Studies Type 2 Diabetes Prevention Studies Both behavioral and pharmacologic ... ... |
|
8. Relative Risk of CVD in Subjects With and Without Diabetes Framingham Relative Risk of CVD in Subjects With and Without Diabetes: Framingham Heart Study A 16-year follow-up of the Framingham Heart Study demonstrated that patients with diabetes are at substantially higher risk of overt cardiovascular disease (CVD) than those without diabetes. Among the patients with diabetes, the age-adjusted risks for any cardiovascular event—intermittent claudication, cardiac failure, and CHD, including myocardial ... ... |
|
9. Lower Extremity Amputations in People With Diabetes, 1996 Lower Extremity Amputations in People With Diabetes, 1996 Lower extremity amputations in diabetic patients result from a combination of peripheral neuropathy (unnoticed trauma, altered structure of the foot) and lower-extremity arterial disease (poor circulation and wound healing). Over half of all nontraumatic lower extremity amputations occur in patients with diabetes. Available at: >A href="http://www.cdc.gov/diabetes/... ... |
|
10. Relative Risk of Mortality in People With Diabetes Relative Risk of Mortality in People with Diabetes This slide, which is based on data obtained in North Dakota, shows the relative risk of death in people with diabetes as compared with individuals without diabetes in the age groups in which type 2 diabetes is most common. Risk of death increased three- to fivefold for ages 45 to 64 and two- to threefold for ages 65 to 74. The relative risk declines with advancing age as mortality ... ... |
|
11. Mortality in People With Diabetes US Population Mortality in People With Diabetes: US Population Preliminary 2000 data from the National Center for Health Statistics lists diabetes as the sixth leading cause of death in the United States. This slide shows mortality attributable to diabetes among the diabetic population in the United States. Available at: http://www.cdc.gov/diabetes/statistics/surv199/... ... |
|
12. Prevalence of Diagnosed and Undiagnosed Diabetes and IFG in US Populations 20+ Years by Sex and Racial-Ethnic Group Prevalence of Diagnosed and Undiagnosed Diabetes and IFG in US Population >20 Years by Sex and Racial/Ethnic Group This figure (based on the Third National Health and Nutrition Examination Survey [1998-1994]) illustrates the prevalence by sex of diagnosed diabetes, undiagnosed diabetes, and impaired fasting glucose (IFG) in three racial/ethnic groups in US adults 20 years of age and older—non-Hispanic whites, non-Hispanic ... ... |
|
13. Prevalence of Obesity in the United States Prevalence of Obesity in the United States The prevalence of obesity among US adults increased by 61% from 1991 to 2000, according to data obtained through the Behavioral Risk Factor Surveillance System (BRFSS), which conducted telephone interviews with 184,450 people aged 18 years and older in 50 states in 2000. According to BRFSS data, 38.8 million US adults (19.6 million men, 19.2 million women) were obese (body mass index [BMI... ... |
|
14. Prevalence of Diabetes in the United States Prevalence of Diabetes in the United States The prevalence of diagnosed diabetes among US adults increased by 49% in a single decade, from 4.9% in 1990 to 7.3% in 2000. Mississippi had the highest rate (8.8%) of diagnosed diabetes in 2000, and Alaska had the lowest (4.4%). Analysis of the 2000 data according to education showed that people with less than a high school education had the highest ... ... |
|
15. UKPDS Summary UKPDS: Summary Over a 10-year period, intensive treatment with sulfonylurea or insulin provided an 11% proportional reduction in HbA1c levels relative to conventional treatment with dietary therapy. The better glycemic control afforded by intensive treatment relative to conventional treatment was accompanied by a significant 25% risk reduction in microvascular complications (P=0.0099) and a 16% risk reduction in MI (including ... ... |
|
16. UKPDS Key Messages (cont'd) STRONG> Blood glucose levels increase with increasing duration of diabetes. Recently approved glucose-lowering drugs not available to the UKPDS may prevent or at least retard this rise in blood glucose over time. The complex study design of the UKPDS makes comparison of the different intensive therapies difficult. ... |
|
17. UKPDS Key Messages UKPDS Key Messages UKPDS results suggest that intensive control of blood glucose and HbA1c levels significantly reduces the risk of microvascular complications. In addition, the UKPDS investigators observed that tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in risk of diabetes-related death. Epidemiologic analysis of study results revealed a ... ... |
|
18. UKPDS Glycemic Control--Effects on Microvascular Endpoints UKPDS: Glycemic Control—Effects on Microvascular Endpoints With respect to microvascular complications, epidemiologic analysis revealed that a continuous and significant relation exists between the hazard ratio of microvascular endpoints and glycemia over time as represented by an updated mean of annual measurements of HbA1c for every percentage point decrease in HbA1c (eg, 9% to 8%), the risk of complications was reduced by 37%>... ... |
|
19. UKPDS Summary (cont'd) STRONG> With regard to BP, tight control in patients with type 2 diabetes and hypertension resulted in significant reductions in microvascular complications, stroke, and congestive heart failure. The UKPDS found that for every 1% reduction in updated HbA1c, there was a 21% decrease in risk for any diabetes-related endpoint; a 21% decrease in risk for any diabetes-related mortality; and a 14% decrease in risk for all-cause mortality. In sum, results of the ... ... |
|
20. UKPDS Summary (cont'd) STRONG> Unfortunately, the data from the UKPDS on the effect of intensive control on macrovascular outcomes are inconclusive. With metformin monotherapy, significant reductions in macrovascular complications were observed, but diabetes-related mortality appeared to increase in patients who received sulfonylureas plus metformin. UK Prospective Diabetes Study (UKPDS) Group. ... |
|
21. UKPDS Summary UKPDS Summary In summary, the UKPDS results have several important implications for the management of patients with type 2 diabetes. Intensive glycemic control results in significant reductions in the risk of microvascular complications. Despite adjustments in medication dosage, UKPDS investigators observed a trend toward worse glycemic control over time. ... |
|
22. UKPDS Risk Reduction in Diabetes-Related Complications Updated Systolic BP UKPDS: Risk Reduction in Diabetes-Related Complications (Updated Systolic BP) Data from the UKPDS indicate that risk for diabetes-related complications improved significantly with reductions in systolic BP. Conversely, a higher risk for these complications was seen with elevations in systolic BP. The researchers did not identify a threshold systolic BP level associated with the onset of any of the diabetes-related ... ... |
|
23. UKPDS Risk Reduction in Diabetes-Related Endpoints and Mortality Updated Systolic BP UKPDS: Risk Reduction in Diabetes-Related Endpoints and Mortality (Updated Systolic BP) In the UKPDS, a Cox regression analysis revealed that the risks of any diabetes-related endpoint and death related to diabetes were associated with higher systolic BP levels. As shown on this slide, for every 10 mm Hg reduction in systolic BP, there was a 12% decline in any diabetes-related endpoint and a 17% decrease in diabetes-related mortality... ... |
|
24. UKPDS Incidence of Diabetes Related Endpoints by Updated Mean Systolic BP UKPDS: Incidence of Diabetes-Related Endpoints by Updated Mean Systolic BP In this prospective observational analysis of UKPDS data, the incidence of diabetes-related complications was associated with systolic BP over time. Patients were categorized by systolic BP measurements into the following groups: <120 mm Hg, 120 to 129 mm Hg, 130 to 139 mm Hg, 140 to 149 mm Hg, 150 to 159 mm Hg, and >160 mm Hg. There was a twofold rise ... ... |
|
25. UKPDS Results Tight BP Control UKPDS Results: Tight BP Control During a median follow-up of 8.4 years, mean BP was significantly reduced in the group assigned to tight control compared with the group assigned to less tight control. Compared with less tight control, tight BP control was associated with clinically important reductions in both microvascular and macrovascular complications of diabetes. In general, the magnitude of the risk ... ... |
| More results... | |
|
